Icosavax Inc (DELISTED) (ICVX:DL)
15.31
0.00 (0.00%)
USD |
NASDAQ |
Feb 29, 16:00
Icosavax Research and Development Expense (Quarterly): 16.67M for Sept. 30, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 16.67M |
| June 30, 2023 | 19.83M |
| March 31, 2023 | 17.36M |
| December 31, 2022 | 16.19M |
| September 30, 2022 | 15.48M |
| June 30, 2022 | 15.82M |
| March 31, 2022 | 17.91M |
| December 31, 2021 | 14.06M |
| Date | Value |
|---|---|
| September 30, 2021 | 10.88M |
| June 30, 2021 | 8.277M |
| March 31, 2021 | 5.553M |
| December 31, 2020 | 5.329M |
| September 30, 2020 | 4.752M |
| June 30, 2020 | 4.666M |
| March 31, 2020 | 2.92M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.92M
Minimum
Mar 2020
19.83M
Maximum
Jun 2023
11.71M
Average
14.06M
Median
Dec 2021
Research and Development Expense (Quarterly) Benchmarks
| Karuna Therapeutics Inc (DELISTED) | 82.19M |
| Immunogen Inc (DELISTED) | 47.57M |
| AbbVie Inc | 1.939B |
| Assure Holdings Corp | -- |
| Harpoon Therapeutics Inc (DELISTED) | 12.32M |